Clene Inc. — Investor Relations & Filings

Clene Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing nanotherapeutics to treat neurodegenerative diseases. The company's approach centers on its proprietary technology platform, which creates clean-surfaced, catalytically-active nanocrystals. These nanotherapeutics are designed to address cellular energy impairments, a key factor in the progression of many neurological conditions. By targeting these bioenergetic deficits, Clene aims to restore and protect neuronal health and function. The company is advancing a pipeline of drug candidates to address high unmet medical needs in diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.